When a rheumatologist prescribes Humira instead of a biosimilar, or an oncologist insists on Ocrevus over a generic alternative, it’s not because they’re ignoring cost-it’s because they’ve seen what happens when patients switch. In specialty prescribing, brand-name drugs aren’t just preferred; they’re often the only option that works. And the reasons go far beyond marketing. Specialty drugs aren’t your typical prescriptions. These aren’t antibiotics or blood pressure pills. They’re high-cost, complex treatments for conditions like multiple sclerosis, rheumatoid arthritis, cancer, and rare genetic disorders. They’re often injected or infused. They need special storage. They require ongoing monitoring. And they’re expensive-sometimes over $100,000 a year per patient. According to data from the Medicare Part D program, specialty drugs made up just 0.5% of all prescriptions in 2019, but they accounted for 54% of all brand-name drug spending. By 2023, that share had climbed to 68%. In other words, a tiny fraction of prescriptions are driving the majority of drug costs. Why do specialists keep reaching for the brand-name version? It’s not about loyalty to a company. It’s about real-world outcomes. In 2021, a study in the Journal of Managed Care & Specialty Pharmacy found that specialty drugs represented only 6.2% of prescriptions but 71.1% of total drug spending. That’s because these drugs treat conditions with few alternatives. For example, a patient with a rare mutation of multiple sclerosis might respond to Ocrevus but have no meaningful response to any biosimilar. The difference isn’t theoretical-it’s measured in relapse rates, hospitalizations, and quality of life. The financial burden falls hardest on patients. The average annual cost for a specialty drug user is $38,000. For someone on a non-specialty drug? $492. That’s a 75-fold difference. And while generics make up 90% of all prescriptions, they account for just 17.5% of total spending. Specialty drugs flip that ratio. When a patient’s insurance plan changes, their copay can jump from $50 to $850 overnight. A Reddit user in November 2023 described paying $1,200 a month for Ocrevus-even with insurance-because their specialist said no other drug matched their specific condition. Prescribers aren’t blind to the cost. In fact, a 2023 Medscape survey of 1,200 specialists found that 68% were frustrated by prior authorization delays for specialty drugs. Oncologists and rheumatologists reported the highest stress levels. But when a patient’s life depends on getting the right drug on time, specialists prioritize efficacy over cost. One rheumatologist in Chicago told me, "I’ve seen patients go into remission on Humira. I’ve seen others flare badly after switching to a biosimilar. I can’t risk it." The system itself makes switching harder. Specialty drugs often come with complex distribution networks. Only certain pharmacies-called specialty pharmacies-are authorized to handle them. These pharmacies work closely with manufacturers and pharmacy benefit managers (PBMs). The Federal Trade Commission found that the "Big 3" PBMs-Caremark Rx, Express Scripts, and OptumRx-generated over $7.3 billion in revenue between 2017 and 2022 from dispensing specialty drugs at prices far above what they paid to acquire them. And here’s the kicker: those markups were even higher on specialty generics. One report showed markups of thousands of percent on drugs that should’ve been cheap. This isn’t just about PBMs. It’s about how the system is built. Drug manufacturers design their own patient support programs, which include copay assistance, nurse educators, and delivery logistics. These programs are often tied to brand-name drugs. Generic versions rarely have the same level of support. So even if a generic exists, the patient might not get the help they need to take it correctly. A 2023 FDA review found that only 65% of specialty drug manufacturers provided clear guidance on how to manage their risk programs. That means doctors can’t trust the process. There’s also the issue of clinical inertia. When a patient is stable on a brand-name drug, switching is risky. The FDA approves biosimilars based on similarity-not identicality. And for conditions like autoimmune diseases, even small differences in protein structure can trigger immune responses. A 2021 JAMA Network Open study showed that prescriber- or patient-requested branded dispensing added $1.67 billion in costs to Medicare and $270 million to patients annually. But the alternative? A flare-up, a hospital stay, or worse. And then there’s the influence of data-not from ads, but from real outcomes. Dr. Peter Bach from Memorial Sloan Kettering says, "The current system allows manufacturers to set prices without meaningful competition, especially for specialty drugs with limited therapeutic alternatives." That’s not conspiracy theory-it’s market reality. When there are only two or three drugs that work for a rare disease, the manufacturer has power. And specialists know it. The system is also slow to adapt. Getting started with specialty prescribing means enrolling in specialty pharmacy networks, which can take weeks. Physicians spend an average of 13.4 hours per week just on prior authorization paperwork, and 78% of that time is spent on specialty drugs. That’s not time spent with patients. It’s time spent fighting insurance companies. Still, change is coming. The Inflation Reduction Act of 2022 lets Medicare negotiate prices for some high-cost drugs. Drugs like Jakafi, Ofev, and Xtandi are already on the list. The Centers for Medicare & Medicaid Services proposed new rules in March 2025 that would force PBMs to disclose how much they’re marking up specialty drugs. And Senator Bernie Sanders introduced the "Specialty Drug Price Transparency Act" in February 2025 to tackle the 42% annual growth in PBM excess revenue. But until those changes fully take effect, specialists will keep prescribing brand-name drugs-not because they’re paid to, but because they’ve seen the consequences of doing otherwise. The data doesn’t lie: when patients switch, sometimes they get worse. And for a rheumatologist, oncologist, or neurologist, that’s not a risk they’re willing to take. The truth is, specialty prescribing isn’t about greed or bias. It’s about survival-for patients, for providers, and for the system itself. Until we fix the underlying pricing and distribution flaws, brand-name drugs will remain the default. Not because they’re expensive. But because, in many cases, they’re the only thing that works.

What drives specialists to choose brand-name drugs?

Specialists don’t choose brand-name drugs lightly. They do it because:

• There are few or no effective alternatives for many rare or complex conditions.
• Biosimilars and generics may not trigger the same immune response or clinical outcomes.
• Patient support programs (nurse educators, delivery, copay help) are tied almost exclusively to brand-name drugs.
• Switching can lead to disease flares, hospitalizations, or loss of function.
• Prior authorization delays and insurance barriers make switching logistically risky.

How do PBMs affect specialty drug prescribing?

Pharmacy benefit managers (PBMs) control how specialty drugs are distributed and priced. The "Big 3" PBMs-Caremark Rx, Express Scripts, and OptumRx-handle over two-thirds of specialty drug dispensing in the U.S. They don’t just negotiate prices-they mark them up. The Federal Trade Commission found that between 2017 and 2021, PBMs charged pharmacies thousands of percent more than what they paid for specialty generics. This profit margin is hidden from patients and even many providers. The result? Patients pay more, insurers pay more, and the system becomes less transparent.

Why are specialty drug costs so hard to control?

Specialty drugs are expensive because:

• They treat conditions with no other treatment options.
• Manufacturers have little competition, so they set high prices.
• Complex distribution channels (specialty pharmacies, PBMs, patient support programs) add layers of cost.
• There’s no price negotiation power for many drugs, especially those for rare diseases.
• Patients can’t easily switch, so demand stays high regardless of price.

What’s being done to fix the system?

Several reforms are underway:

• The Inflation Reduction Act allows Medicare to negotiate prices for select high-cost drugs, including some specialty medications.
• The Centers for Medicare & Medicaid Services proposed new rules in March 2025 requiring PBMs to disclose pricing markups.
• The "Specialty Drug Price Transparency Act" (2025) aims to stop the 42% annual growth in PBM excess revenue.
• More states are requiring transparency in specialty pharmacy contracts.

What can patients do if their specialist won’t switch to a cheaper option?

If your specialist refuses to switch from a brand-name drug:

• Ask for the clinical reason-what data or experience supports their decision?
• Request a copy of your treatment history and response to previous medications.
• Ask if the manufacturer offers a patient assistance program for the brand-name drug.
• Check if your insurance has a prior authorization exception process for medical necessity.
• Reach out to organizations like the National Organization of Rare Disorders (NORD), which helped 45,000 patients access specialty drugs in 2023.

How do insurance plans impact specialty drug access?

Insurance plans control access through formularies, tiering, and prior authorization. Many plans put specialty drugs on the highest tier, meaning patients pay the most out-of-pocket. When plans change their formulary mid-year, patients can face sudden copay spikes-from $50 to $850 in a single month. Specialists often have to appeal these decisions, which can delay treatment by weeks. Some insurers now require step therapy: try a cheaper drug first. But for many specialty conditions, that step leads to failure, not success.

Is there evidence that specialists are influenced by pharmaceutical companies?

Yes, but it’s not the full story. A 2016 ProPublica analysis found that doctors who received over $5,000 from drug companies in 2014 prescribed brand-name drugs 50% more often than those who received nothing. But specialists in oncology, rheumatology, and neurology rarely rely on reps. Their decisions are shaped by clinical trials, real-world outcomes, and patient safety-not marketing. The bigger influence is systemic: when only one drug has proven efficacy, and support systems are tied to it, prescribing becomes inevitable.

What’s the future of specialty drug prescribing?

By 2028, specialty drugs are projected to make up 73% of global prescription drug spending. The pipeline includes over 2,700 new investigational drugs, nearly half targeting rare diseases. But sustainability is in question. The Congressional Budget Office predicts specialty drugs will consume 60% of Medicare Part D spending by 2030. Without structural changes-like price negotiation, PBM transparency, and better generic competition-costs will keep rising. The question isn’t whether specialists will keep prescribing brand-name drugs. It’s whether the system can afford to let them.

What role do specialty pharmacies play?

Specialty pharmacies are the backbone of specialty drug delivery. They handle storage, shipping, patient education, and adherence monitoring. Unlike regular pharmacies, they work directly with manufacturers and PBMs. There are about 12,500 certified specialty pharmacists in the U.S., trained to manage complex regimens. But they’re also caught in the middle: pressured by PBMs to push certain drugs, while trying to ensure patients get the right treatment. Their role is critical-but often invisible to patients.

How do clinical guidelines influence prescribing?

Guidelines from organizations like the American Society of Clinical Oncology and the American College of Rheumatology strongly favor brand-name drugs in many cases. Why? Because the evidence for biosimilars in real-world settings is still limited. Guidelines are based on clinical trials and outcomes data-not cost. When a guideline says "use drug X," specialists follow it. And in many cases, drug X is still the brand-name version.

What are the biggest misconceptions about specialty drug prescribing?

• Misconception: Specialists prescribe brand-name drugs because they get paid to.
  Reality: Most specialists receive no payments from drug companies. Their decisions are based on clinical outcomes and patient safety.
• Misconception: Biosimilars are just as good as brand-name drugs.
  Reality: For some conditions, biosimilars work fine. For others, patients flare, get hospitalized, or lose function after switching.
• Misconception: The system is broken because of greed.
  Reality: The system is broken because of complexity, lack of competition, and misaligned incentives across PBMs, manufacturers, and insurers.